Enliven Therapeutics
ELVN
61 hedge funds and large institutions have $534M invested in Enliven Therapeutics in 2023 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 22 increasing their positions, 22 reducing their positions, and 8 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 22
0.19% less ownership
Funds ownership: 95.15% → 94.96% (-0.19%)
3% less funds holding
Funds holding: 63 → 61 (-2)
17% less funds holding in top 10
Funds holding in top 10: 6 → 5 (-1)
25% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 8
33% less capital invested
Capital invested by funds: $798M → $534M (-$264M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VA
VR Adviser
New York
|
+$12.2M |
| 2 |
CC
Commodore Capital
New York
|
+$9.32M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
+$6.66M |
| 4 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
+$3.7M |
| 5 |
Charles Schwab
San Francisco,
California
|
+$1.59M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$12.1M |
| 2 |
5VM
5AM Venture Management
San Francisco,
California
|
-$10.7M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$5.48M |
| 4 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$3.95M |
| 5 |
Janus Henderson Group
London,
United Kingdom
|
-$1.59M |
ELVN Hedge Fund Activity: Q3 2023 in Review
61 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Enliven Therapeutics (ELVN) for Q3 2023, worth a combined $534M — down 33% from $798M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of ELVN and 6 opened new positions — a net loss of 2 holders — while 22 trimmed existing stakes and 22 added.
The largest buyer was VR Adviser, adding an estimated $12.2M. The largest seller was Cormorant Asset Management, cutting an estimated $12.1M.
- 61 institutional investors held Enliven Therapeutics (ELVN) as of Q3 2023, down from 63 in Q2 2023.
- Funds reported $534M of Enliven Therapeutics stock for Q3 2023, down 33% quarter-over-quarter.
- 6 funds opened new Enliven Therapeutics positions in Q3 2023 and 8 closed out, a net change of -2 holders.
- The largest Enliven Therapeutics buyer in Q3 2023 was VR Adviser, an estimated $12.2M added.
- The largest Enliven Therapeutics seller in Q3 2023 was Cormorant Asset Management, an estimated $12.1M sold.
Based on aggregated 13F filings for Q3 2023.